Medivation posted second-quarter numbers on Tuesday, and they offer more evidence why Big Pharma and Big Biotech are stumbling over themselves to snap up the…

Two years after threatening to sue AbbVie for abandoning its $55 billion Shire buyout, hedge fund Elliott Management finally did.

Pfizer and Allergan weren’t the only ones that were unhappy with the U.S. Treasury’s April move to block their $160 billion proposed megamerger.

The industry is abuzz with a potential Biogen takeover from buyout-inclined Allergan or Merck. But Biogen’s not necessarily into the idea.

When CEO Ian Read launches into Pfizer’s quarterly earnings call, market watchers start looking for crumbs that lead to a split-up of the company. On Tuesday,…

Industry watchers have been predicting that buyers would come for Biogen--and now, they just may have. Merck and Allergan are weighing offers, the WSJ reports…

Rumors have been flying that Stada’s talked with potential buyer CVC Capital Partners--and the way one activist investor sees it, if the drugmaker hasn’t, it…

What with long summer days and vacations, it can be tough to keep up with required reading in July. To catch up with the best-read news, check out FiercePharma…